Dusquetide (also referred to by its research name SGX94) is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability. Preclinical data indicate that dusquetide is active in models of a wide range of therapeutic indications including severe side-effects of chemo- and/or radiation-therapy and life-threatening bacterial infections. Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified. A multi-center, double-blind, placebo-controlled, pivital Phase 3 clinical study in oral mucositis in head and neck cancer patients has been initiated.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. | 2016 Dec 10 |
|
A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. | 2016 May 20 |
|
Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. | 2017 Sep |
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 09:11:37 GMT 2023
by
admin
on
Sat Dec 16 09:11:37 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
IKX7W49NLN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
395913
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
||
|
FDA ORPHAN DRUG |
528016
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71722017
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
PRIMARY | |||
|
C113437
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
PRIMARY | |||
|
10108
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
PRIMARY | |||
|
BC-47
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
PRIMARY | |||
|
931395-42-5
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
PRIMARY | |||
|
IKX7W49NLN
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545314
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
PRIMARY | |||
|
DB11879
Created by
admin on Sat Dec 16 09:11:37 GMT 2023 , Edited by admin on Sat Dec 16 09:11:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
|